Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.01, read 2026-10-29
Ethical does not pass the values gate
Price38.57 USD
Fair value48.00
Ethical score30.0/100
Our investment reviews on this name
2026-10-11Read Distribution39.07-1.3% to today ✓Markdown gives way to Distribution with deal news in the headlines
2026-09-09Read Markdown39.99-3.6% to today ✓Markup gives way to Markdown
2026-08-08Read Markup41.75-7.6% to today Accumulation gives way to Markup after a 14% rise in 5 weeks
2026-07-02Read Accumulation36.60+5.4% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Peoples Bancorp Inc. holds its Accumulation at $38.57. Consolidating, no directional conviction, held for 76 days.
As held on the ledger · 2026-10-30
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 76 days
Price at the screen
$38.57
Valuation
11.34 trailing · 9.19 forward price to earnings
Values screen
FAIL· score 30.0
Beta
0.61
The Workings
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: bank
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Prohibited keyword in sector/industry: bank
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Peoples Bancorp does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-01. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PEBO's ethical verdict changes
Today PEBO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. A 24.4% margin of safety to the base estimate.
Where our models see it going: fair-value estimate $48.00, with a range of $47.06 to $77.14, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why this regional bank fails our screen
Walk into any Ohio branch and the same story plays out: customers deposit pay cheques, businesses borrow for trucks, and the bank earns a steady spread. Peoples Bancorp does exactly that job, nothing more. The numbers look ordinary, revenue up 7 percent, a 26 percent profit margin and 9 percent return on equity, yet the market prices the shares at 10.5 times forward earnings with a consensus target that matches the current quote. None of that matters once the ethical screen is applied.
We pass for one clear reason. The business sits inside a sector the screen rules out on principle. No valuation cushion or modest growth rate changes that verdict, even when fair value sits 9 percent above the last trade.
The real risk is simple. Regional banks carry credit cycles, rate swings and thin capital buffers that can turn a low multiple into a trap rather than a bargain. Add the ethical block and there is no case left to consider.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PEBO trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-27Distribution$35.79+0.0%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37. Insiders have been net sellers over the past quarter.
2026-10-20Distribution$35.79+0.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Distribution$35.79+0.0%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Distribution$35.79+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Distribution$35.79+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Distribution$35.79+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Distribution$35.790.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Distribution$35.80+0.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-13Distribution$35.80-8.4%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (6 analysts) rates it none, with a mean price target of $37.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
